Schrodinger
Open
$11.94
Prev. Close
$11.93
High
$11.97
Low
$11.94
Market Snapshot
$866.3M
-8.4
-2.57
$207.54M
850
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 850 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
emptyResult
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 850 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Recently from Cashu
Schrödinger Set to Announce 2024 Financial Results Amidst Molecular Science Innovations
Schrödinger Poised to Reveal Financial Insights Amidst Ongoing Innovation in Molecular Science Schrödinger, a leader in the realm of computational molecular discovery, prepares to announce its fourth-…
Schrödinger Strengthens Talent Acquisition with Restricted Stock Units for New Employees
Schrödinger Enhances Talent Acquisition Strategy with Restricted Stock Units Schrödinger, Inc. makes a strategic move in attracting top talent by granting restricted stock units (RSUs) to four new emp…
Schrödinger Boosts Innovation with Strategic Talent Acquisition and Restricted Stock Units
Schrödinger's Strategic Talent Acquisition Boosts Innovative Potential Schrödinger, Inc. continues to strengthen its workforce and enhance its innovative capabilities with the recent grant of restrict…
Schrödinger: Leading Innovations in Molecular Discovery and Drug Development
Schrödinger’s Innovations at the Forefront of Molecular Discovery Schrödinger, Inc. is positioning itself as a leader in the field of molecular discovery, leveraging over three decades of expertise in…